2012: A Good, Bad or Ugly Year for Servier? - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

2012: A Good, Bad or Ugly Year for Servier?
The scandal surrounding Servier's diabetes drug, Mediator, continues to unravel in France and could have implications for the whole pharmaceutical industry as the country scrutinises its regulatory systems.


Pharmaceutical Technology Europe
Volume 24, Issue 2

References

1. E. Lanez, "Mediator : l'effarante boîte à mensonges" (Le Point.fr, 2011) http://www.lepoint.fr, accessed Jan. 9, 2012.

2. B. Casassus, "With New Law, France Revamps Drug Approval" (Science, 2011). http://news.sciencemag.org/, accessed Jan. 9, 2012.

3. Servier, "Research is as vital as being an industry " (Servier website, 2011). http://www.servier.com/, accessed 9 Jan., 2012.

4. J. Upton, "Servier: patience and passion," Pharmaceutical Executive Europe (November 2008).

5. Focus Reports, "Interview—Jacques Servier" (2011). http://www.pharma.focusreports.net/, accessed 9 Jan., 2012.

6. K. Grogan, "Servier signs cancer deal with Sweden's BioInvent" (Pharma Times, 2012). http://www.pharmatimes.com/, accessed Jan. 9, 2012.

7. European Biotechnology Science & Industry News "Galapagos gets €4 million in alliance with Servier" (2011). http://www.eurobiotechnews.eu, accessed 9 Jan., 2012.

8. N. Jessop, Pharm. Technol. Eur. 23 (3), 14–18 (2011).

9. Le Point.fr, "Mediator, un jugement pour 2012?" (2011). http://www.lepoint.fr, accessed Jan. 9, 2012.

10. S. Sayare, "Scandal Over Mediator, a French Weight-Loss Drug, Prompts Calls for Wide Changes" (New York Times, 2011). http://www.nytimes.com/, accessed Jan. 9, 2012

11. Assemblée Nationale (2011). http://www.assemblee-nationale.fr/13/rap-info/i3552.asp, accessed Jan. 11, 2012

12. InPharm, "2011 Year In Review" (2012). http://www.inpharm.com/, accessed Jan. 9, 2012.

13. Le Nouvel Observateur, "Mediator: la cour rejette le regroupement des procédures" (2011). http://tempsreel.nouvelobs.com/, accessed Jan. 11, 2012.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
27%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
32%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology Europe,
Click here